ParkinsonFranceV1, Ncbi, Curation, bibRecord, 001909

Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.

Identifieur interne : 001909 ( Ncbi/Curation ); précédent : 001908; suivant : 001910

Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.

Auteurs : Clément François [États-Unis] ; Robert A. Hauser [États-Unis] ; Samuel Aballéa [France] ; Julie Dorey [États-Unis] ; Elizaveta Kharitonova [France] ; L Arthur Hewitt [États-Unis]

Source :

Journal of medical economics [ 1941-837X ] ; 2016.

RBID : pubmed:26710315

English descriptors

KwdEn :
- Accidental Falls (economics), Aged, Antiparkinson Agents (economics), Antiparkinson Agents (therapeutic use), Blood Pressure, Cost-Benefit Analysis, Dose-Response Relationship, Drug, Double-Blind Method, Droxidopa (economics), Droxidopa (therapeutic use), Female, Humans, Hypotension, Orthostatic (drug therapy), Hypotension, Orthostatic (etiology), Male, Markov Chains, Parkinson Disease (complications), Quality-Adjusted Life Years.
MESH :
- chemical , economics : Antiparkinson Agents, Droxidopa.
- complications : Parkinson Disease.
- drug therapy : Hypotension, Orthostatic.
- economics : Accidental Falls.
- etiology : Hypotension, Orthostatic.
- chemical , therapeutic use : Antiparkinson Agents, Droxidopa.
- Aged, Blood Pressure, Cost-Benefit Analysis, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Markov Chains, Quality-Adjusted Life Years.

Abstract

Falls are associated with neurogenic orthostatic hypotension (nOH) and are an economic burden on the US healthcare system. Droxidopa is approved by the US FDA to treat symptomatic nOH. This study estimates the cost-effectiveness of droxidopa vs standard of care from a US payer perspective.

DOI: 10.3111/13696998.2015.1136827
PubMed: 26710315

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000220
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000219
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000219
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001909

Links to Exploration step

pubmed:26710315

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.</title>
<author><name sortKey="Francois, Clement" sort="Francois, Clement" uniqKey="Francois C" first="Clément" last="François">Clément François</name>
<affiliation wicri:level="2"><nlm:affiliation>a a Lundbeck LLC , Deerfield , IL , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a a Lundbeck LLC , Deerfield , IL </wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A" last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="2"><nlm:affiliation>b b University of South Florida , Tampa , FL , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b b University of South Florida , Tampa , FL </wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Aballea, Samuel" sort="Aballea, Samuel" uniqKey="Aballea S" first="Samuel" last="Aballéa">Samuel Aballéa</name>
<affiliation wicri:level="1"><nlm:affiliation>c c Creativ-Ceutical , Paris , France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>c c Creativ-Ceutical , Paris </wicri:regionArea>
<wicri:noRegion>Paris </wicri:noRegion>
<wicri:noRegion>Paris </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dorey, Julie" sort="Dorey, Julie" uniqKey="Dorey J" first="Julie" last="Dorey">Julie Dorey</name>
<affiliation wicri:level="2"><nlm:affiliation>d d Creativ-Ceutical USA Inc. , Chicago , IL , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>d d Creativ-Ceutical USA Inc. , Chicago , IL </wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kharitonova, Elizaveta" sort="Kharitonova, Elizaveta" uniqKey="Kharitonova E" first="Elizaveta" last="Kharitonova">Elizaveta Kharitonova</name>
<affiliation wicri:level="1"><nlm:affiliation>c c Creativ-Ceutical , Paris , France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>c c Creativ-Ceutical , Paris </wicri:regionArea>
<wicri:noRegion>Paris </wicri:noRegion>
<wicri:noRegion>Paris </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hewitt, L Arthur" sort="Hewitt, L Arthur" uniqKey="Hewitt L" first="L Arthur" last="Hewitt">L Arthur Hewitt</name>
<affiliation wicri:level="2"><nlm:affiliation>a a Lundbeck LLC , Deerfield , IL , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a a Lundbeck LLC , Deerfield , IL </wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:26710315</idno>
<idno type="pmid">26710315</idno>
<idno type="doi">10.3111/13696998.2015.1136827</idno>
<idno type="wicri:Area/PubMed/Corpus">000220</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000220</idno>
<idno type="wicri:Area/PubMed/Curation">000219</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000219</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000219</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000219</idno>
<idno type="wicri:Area/Ncbi/Merge">001909</idno>
<idno type="wicri:Area/Ncbi/Curation">001909</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.</title>
<author><name sortKey="Francois, Clement" sort="Francois, Clement" uniqKey="Francois C" first="Clément" last="François">Clément François</name>
<affiliation wicri:level="2"><nlm:affiliation>a a Lundbeck LLC , Deerfield , IL , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a a Lundbeck LLC , Deerfield , IL </wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A" last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="2"><nlm:affiliation>b b University of South Florida , Tampa , FL , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b b University of South Florida , Tampa , FL </wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Aballea, Samuel" sort="Aballea, Samuel" uniqKey="Aballea S" first="Samuel" last="Aballéa">Samuel Aballéa</name>
<affiliation wicri:level="1"><nlm:affiliation>c c Creativ-Ceutical , Paris , France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>c c Creativ-Ceutical , Paris </wicri:regionArea>
<wicri:noRegion>Paris </wicri:noRegion>
<wicri:noRegion>Paris </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dorey, Julie" sort="Dorey, Julie" uniqKey="Dorey J" first="Julie" last="Dorey">Julie Dorey</name>
<affiliation wicri:level="2"><nlm:affiliation>d d Creativ-Ceutical USA Inc. , Chicago , IL , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>d d Creativ-Ceutical USA Inc. , Chicago , IL </wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kharitonova, Elizaveta" sort="Kharitonova, Elizaveta" uniqKey="Kharitonova E" first="Elizaveta" last="Kharitonova">Elizaveta Kharitonova</name>
<affiliation wicri:level="1"><nlm:affiliation>c c Creativ-Ceutical , Paris , France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>c c Creativ-Ceutical , Paris </wicri:regionArea>
<wicri:noRegion>Paris </wicri:noRegion>
<wicri:noRegion>Paris </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hewitt, L Arthur" sort="Hewitt, L Arthur" uniqKey="Hewitt L" first="L Arthur" last="Hewitt">L Arthur Hewitt</name>
<affiliation wicri:level="2"><nlm:affiliation>a a Lundbeck LLC , Deerfield , IL , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>a a Lundbeck LLC , Deerfield , IL </wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of medical economics</title>
<idno type="eISSN">1941-837X</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Accidental Falls (economics)</term>
<term>Aged</term>
<term>Antiparkinson Agents (economics)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Blood Pressure</term>
<term>Cost-Benefit Analysis</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Droxidopa (economics)</term>
<term>Droxidopa (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Hypotension, Orthostatic (drug therapy)</term>
<term>Hypotension, Orthostatic (etiology)</term>
<term>Male</term>
<term>Markov Chains</term>
<term>Parkinson Disease (complications)</term>
<term>Quality-Adjusted Life Years</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Droxidopa</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypotension, Orthostatic</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Accidental Falls</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Hypotension, Orthostatic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Droxidopa</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Blood Pressure</term>
<term>Cost-Benefit Analysis</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Markov Chains</term>
<term>Quality-Adjusted Life Years</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Falls are associated with neurogenic orthostatic hypotension (nOH) and are an economic burden on the US healthcare system. Droxidopa is approved by the US FDA to treat symptomatic nOH. This study estimates the cost-effectiveness of droxidopa vs standard of care from a US payer perspective.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001909 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001909 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:26710315
   |texte=   Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:26710315" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.

Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki